We are live on
!
Find out more
SCM
Sio Capital Management Portfolio holdings
AUM
$697M
1-Year Est. Return
79.73%
This Fund
S&P 500
This Quarter
Est. Return
-15.5%
1 Year Est. Return
+79.73%
3 Year Est. Return
+576.62%
5 Year Est. Return
+422.76%
10 Year Est. Return
+2,506.65%
AUM
$336M
AUM Growth
-$19.6M
(-5.5%)
Cap. Flow
+$53.2M
Cap. Flow
% of AUM
15.83%
Top 10 Holdings %
Top 10 Hldgs %
64.26%
Holding
65
New
14
Increased
15
Reduced
7
Closed
11
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$25.3M |
| 2 |
Neurocrine Biosciences
NBIX
|
+$23.8M |
| 3 |
Globus Medical
GMED
|
+$17.1M |
| 4 |
Embecta
EMBC
|
+$10.9M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
+$9.49M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cigna
CI
|
+$27.1M |
| 2 |
Sanofi
SNY
|
+$18.7M |
| 3 |
Viatris
VTRS
|
+$9.09M |
| 4 |
Organon & Co
OGN
|
+$9.05M |
| 5 |
Labcorp
LH
|
+$7.14M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 88.81% |
| 2 | Industrials | 9.51% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
NextCure
NXTC
$22.7M
| $62.4K | 0.02% |
10,833
| – | – |
|
|
TERN
52
DELISTED
Terns Pharmaceuticals
TERN
| $27.6K | 0.01% |
10,000
| – | – |
|
53
Humacyte Inc Warrant
HUMAW
$1.4M
| $18.1K | 0.01% |
49,998
| – | – |
|
54
Rocket Pharmaceuticals Warrant
RCKTW
$310K
| $17.1K | 0.01% |
400,000
| – | – |
|
55
C4 Therapeutics
CCCC
$402M
| – | – |
-155,000
| Closed | -$558K |
|
|
56
Cigna
CI
$72.7B
| – | – |
-98,003
| Closed | -$27.1M |
|
|
CRGX
57
DELISTED
CARGO Therapeutics
CRGX
| – | – |
-473,292
| Closed | -$6.82M |
|
|
MESO
58
Mesoblast
MESO
$2.03B
| – | – |
-11,600
| Closed | -$230K |
|
59
Neumora Therapeutics
NMRA
$304M
| – | – |
-636,300
| Closed | -$6.74M |
|
60
Nuvation Bio
NUVB
$2.13B
| – | – |
-668,115
| Closed | -$1.78M |
|
|
61
Organon & Co
OGN
$3.56B
| – | – |
-606,410
| Closed | -$9.05M |
|
|
62
Sanofi
SNY
$104B
| – | – |
-387,000
| Closed | -$18.7M |
|
|
63
Viatris
VTRS
$19B
| – | – |
-730,000
| Closed | -$9.09M |
|
64
Q32 Bio
QTTB
$482M
| – | – |
-697,413
| Closed | -$2.4M |
|
|
ACOG
65
Alpha Cognition
ACOG
$189M
| – | – |
-434,700
| Closed | -$2.56M |
|
Similar funds
GUB
KLI
JA
AAM
TCM
CA
SAM
ACM
Sio Capital Management's Q1 2025 Portfolio in Review
As of Q1 2025, Sio Capital Management held 65 positions worth $336M, down 5.5% from $355M the previous quarter. Its ten largest holdings account for 64% of the portfolio.
Sio Capital Management deployed $53.2M of net new capital in Q1 2025, opening 14 new positions and adding to 15 existing holdings. Its largest new stake was Merck: 270,596 shares worth $24.3M.
By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 92% a quarter earlier, followed by Industrials.
On the sell side, the largest reduction was Labcorp, an estimated $7.14M trimmed.
- Sio Capital Management's largest Q1 2025 buy was Merck: 270,596 shares worth $24.3M.
- Sio Capital Management added most to Embecta in Q1 2025, an estimated $10.9M increase.
- Sio Capital Management's biggest Q1 2025 reduction was Labcorp, cutting an estimated $7.14M.
- Sio Capital Management fully exited Cigna in Q1 2025, selling an estimated $27.1M.
- Sio Capital Management's ten largest holdings make up 64% of its $336M portfolio in Q1 2025.
- Sio Capital Management opened 14 new positions and closed 11 in Q1 2025.
- Sio Capital Management's portfolio value fell 5.5% quarter-over-quarter to $336M.
Based on Sio Capital Management's 13F filing for Q1 2025, filed 15 May 2025.